$471 Million is the total value of Opaleye Management Inc.'s 39 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 60.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OCUL | Sell | OCULAR THERAPEUTIX INC | $41,644,000 | -35.7% | 5,974,800 | -7.8% | 8.83% | -27.0% |
| CLDX | Sell | CELLDEX THERAPEUTICS INC | $32,612,000 | -38.5% | 844,000 | -14.3% | 6.92% | -30.2% |
| SMLR | Sell | SEMLER SCIENTIFIC INC | $15,764,000 | -44.1% | 172,000 | -23.7% | 3.34% | -36.5% |
| KROS | Sell | KEROS THERAPEUTICS INC | $15,549,000 | +11.5% | 265,750 | -24.6% | 3.30% | +26.6% |
| KNSA | Sell | KINIKSA PHARMACEUTICALS LTD | $12,064,000 | -19.1% | 1,025,000 | -21.8% | 2.56% | -8.2% |
| ETON | Sell | ETON PHARMACEUTICALS INC | $10,232,000 | -34.3% | 2,385,000 | -22.8% | 2.17% | -25.4% |
| PCVX | Sell | VAXCYTE INC | $7,513,000 | -16.2% | 315,800 | -10.6% | 1.59% | -4.9% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $5,473,000 | -77.2% | 328,100 | -35.9% | 1.16% | -74.1% |
| MEIP | Sell | MEI PHARMA INC | $3,511,000 | -18.7% | 1,315,000 | -16.0% | 0.74% | -7.7% |
| AVEO | Sell | AVEO BIOSCIENCES INC | $1,235,000 | -56.1% | 263,400 | -42.2% | 0.26% | -50.2% |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -115,015 | -100.0% | -0.08% | – |
| SELB | Exit | SELECTA BIOSCIENCES INC | $0 | – | -106,000 | -100.0% | -0.08% | – |
| AKBA | Exit | AKEBIA THERAPEUTICS INC | $0 | – | -311,300 | -100.0% | -0.17% | – |
| Exit | APTOSE BIOSCIENCES INC | $0 | – | -549,000 | -100.0% | -0.22% | – | |
| Exit | AADI BIOSCIENCES INC | $0 | – | -45,020 | -100.0% | -0.25% | – | |
| DTIL | Exit | PRECISION BIOSCIENCES INC | $0 | – | -163,900 | -100.0% | -0.35% | – |
| LPTX | Exit | LEAP THERAPEUTICS INC | $0 | – | -476,000 | -100.0% | -0.36% | – |
| VIRX | Exit | VIRACTA THERAPEUTICS INC | $0 | – | -258,556 | -100.0% | -0.39% | – |
| SIOX | Exit | SIO GENE THERAPIES INC | $0 | – | -955,000 | -100.0% | -0.39% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -320,800 | -100.0% | -0.57% | – |
| FMTX | Exit | FORMA THERAPEUTICS HOLDINGS INC | $0 | – | -182,950 | -100.0% | -0.79% | – |
| OPTN | Exit | OPTINOSE INC | $0 | – | -1,558,500 | -100.0% | -0.87% | – |
| AFIB | Exit | ACUTUS MEDICAL INC | $0 | – | -590,000 | -100.0% | -0.97% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS IN | $0 | – | -205,381 | -100.0% | -1.30% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -1,460,000 | -100.0% | -1.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.